UNIVERSITA DEGLI STUDI DI SIENA

Their core work

The University of Siena is a mid-sized Italian research university with deep strengths in vaccine development, immunology, and type 1 diabetes research, alongside a distinctive parallel track in digital systems and robotics. Their biomedical teams contribute to major European vaccine infrastructure (TRANSVAC2) and have been central to Ebola and infectious disease vaccine trials. They also run archaeological research programs using advanced remote sensing, and coordinate projects in cyber-physical systems and public engagement with science. Their work spans from lab-bench immunology to field archaeology to AI ecosystems — an unusually broad portfolio for a university of their size.

What they specialise in

How they've shifted over time

In the early H2020 period (2015-2018), Siena focused heavily on biomedical research — Ebola vaccine trials, type 1 diabetes prevention, cancer therapeutics training, and infectious disease alliances — alongside cyber-physical systems and robotics projects. From 2019 onward, their portfolio shifted noticeably toward open innovation, AI ecosystems, rare diseases, and cross-sector technology themes (industry 4.0, cleantech, food tech). This evolution suggests the university is deliberately building bridges between its deep biomedical expertise and broader innovation and technology transfer agendas.

Siena is moving from pure biomedical research toward interdisciplinary innovation platforms, making them an increasingly versatile partner for projects that combine health, digital, and societal dimensions.

How they like to work

Siena primarily joins consortia as a participant (36 of 49 projects) but has meaningful coordination experience with 10 projects led, including a prestigious ERC grant. With 614 unique partners across 68 countries, they operate as a well-connected hub rather than a loyal-to-few-partners institution. This breadth means they bring extensive network access to any consortium, though their typical role is as a specialized scientific contributor rather than the administrative lead.

An exceptionally broad network of 614 unique consortium partners spanning 68 countries — well beyond the EU, indicating global collaborative reach. Their partnerships are distributed across health, digital, and environmental sectors with no single dominant geographic cluster.

What sets them apart

Siena's rare combination of vaccine/immunology expertise with robotics and digital systems research makes them an uncommon partner — most universities this size specialize in one or the other. Their ERC-funded archaeology program adds a genuine humanities dimension that enables participation in cross-cutting societal challenge calls. For consortium builders, Siena offers a single partner that can credibly cover health, digital, and social science work packages without needing three separate institutions.

Highlights from their portfolio

• nEU-Med
  Largest single grant (EUR 2.5M), ERC-funded, coordinated by Siena — a 6-year investigation into early medieval economic networks, demonstrating capacity to lead ambitious long-duration research.
• VSV-EBOPLUS
  EUR 1.6M contribution to the Ebola vaccine systems analysis program — their largest health project and evidence of front-line vaccine trial capability.
• AXIOM
  Coordinated this EUR 985K cyber-physical systems project, showcasing their ability to lead technical digital projects, not just participate in them.